期刊文献+

重庆地区肺炎儿童下呼吸道卡他莫拉菌分离株耐药基因研究 被引量:1

Study on the gene of antimicrobitic resistance of Moraxella catarrhalis isolated from lower respiratory tract of children with pneumonia in Chongqing area
下载PDF
导出
摘要 目的探讨重庆地区儿童卡他莫拉菌(Moraxella catarrhalis,Mc)分离株对β-内酰胺类抗生素的耐药机制,指导临床合理用药,有利于防止诱导该菌耐药性变迁。方法取2006年6—12月住院的肺炎患儿下呼吸道中分离的β-内酰胺酶阳性Mc40株,采用PCR技术扩增其基因组DNA,经限制性内切酶酶切后,行琼脂糖凝胶电泳,分析Mc的耐药基因表达及分型,同时比较不同基因型的临床特点。结果40株β-内酰胺酶阳性卡他莫拉菌的BRO基因型为:36株(90.0%)BRO-1基因阳性,3株(7.5%)BRO-2基因阳性,1株(2.5%)未检测到BRO-1基因和BRO-2基因。BRO-1基因阳性菌对多数β-内酰胺类抗生素的抑菌圈直径小于BRO-2基因阳性菌株。结论重庆地区儿童Mc的产酶株以BRO-1基因为主,少数为BRO-2基因,极少菌株可能为其他型别。 Objective To explore the mechanism of resistance to beta-lactam antibiotics of Moraxella catarrhalis(Mc) in children with lower respiratory tract infection,to guide the rational and objective administration and provide measures of avoiding changes of antimicrobial resistance of Mc.Methods Total 40 strains Mc with positive beta-lactamase were taken from lower respiratory tract of hospitalized children with pneumonia from July to December in 2006.Polymerase chain reaction technology was used to amplify genes.The DNA product of the 40 strains were digested by restriction enzyme(BCgΙ).The expression and type of the drug resistance gene(BRO) for ampicillin according to different strap in agarose gel electrophoresis were analyzed.Clinical characteristics of different genotype was studied.Results Among 40 strains Mc with positive Nitrocefin disk,positive BRO-1 gene was 90.0% while positive BRO-2 gene was 7.5%,and another 2.5% was neither positive BRO-1 gene nor positive BRO-2 gene.BRO-3 or TEM-1 enzyme produced may be the possible cause.The diameter of inhibition zone to beta-lactam antibiotics of Mc was smaller in positive BRO-1 gene than that Mc of positive BRO-2 gene.Conclusions BRO-1 gene was the main genotype of Mc with beta-lactamase positive in our study.
出处 《临床儿科杂志》 CAS CSCD 北大核心 2010年第2期124-127,共4页 Journal of Clinical Pediatrics
基金 国家科技部十五攻关项目资助(No2004BA720A09-01)
关键词 儿童 莫拉菌属 耐药基因 children Moraxella antimicrobiol resistance gene
  • 相关文献

参考文献13

  • 1Leesik H, Ani U, Juhani A, et al. Microbial pathogens of adult community-acquired pneumonia in Southern Estonia [J ]. Medicina, 2006,42 (5) : 384-394 [ Lithuania ].
  • 2Wirth T, Morelli G, Kusecek B, et al. The rise and spread of a new pathogen: seroresistant Moraxella catarrhalis [J ]. Genome Res, 2007,17 ( 11 ) : 1647-1656.
  • 3Karlowsky JA, Thornsberry C, Critchley IA, et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae , and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001 - 2002 TRUST studies in the United States [J]. Autimicrob Agents Chemother, 2003,47 (6) : 1790-1797.
  • 4Verduin CM, Hot C, Fleer A, et ol. Moraxella catarrhalis: from emerging to established pathogen [J]. Clin Microbiol Rev,2002,15( 1 ) : 125-144.
  • 5du Plessis M. Rapid discrimination between BRO betalactamases from clinical isolates of Moraxella catarrhalis using restriction endonuclease analysis [J]. Diagn Microbiol Infect Dis, 2001,39 ( 1 ) : 65-67.
  • 6Bootsma HJ, vanDijk H, Verhoef J, et al. Molecular characterization of the BRO beta-lactamases of Moraxella (Branhamella) catarrhalis [J]. Antimicrob Agents Chemother, 1996,40 (4) : 966-972.
  • 7Levy F, Walker ES. BRO beta-lactamase alleles, antibiotic resistance and a test of the BRO-I selective replacement hypothesis in Moraxella catarrhalis [J]. Antimicrob C hemother, 2004,53 (2) : 371-374.
  • 8McGregor K, Chang B J, Mee B J, et al. Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases [J]. Eur J Clin Microbiol Infect Dis, 1998,17(4) :219-234.
  • 9Koseoglu O, Ergin A, Hascelik G. Evaluation of restriction endonuclease analysis of BRO beta-lactamases in clinical and carrier isolates of Moraxella catarrhalis [J]. Scand J Infect Dis, 2004,36 (6-7) : 431-434.
  • 10Deshpande LM, Sadrer HS, Fritsche TR, et al. Contemporary Prevalence of BRO beta-Lactamases in Moraxella catarrhalis: report from the SENTRY Antimierobial Surveillance Program (North America, 1997 to 2004) [J]. Clin Microbiol,2006,44(10) :3775-3777.

二级参考文献6

  • 1Verduin CM, Hol C, Fleer A, et al. Moraxella catarrhalis:from emerging to established pathogen. Clin Microbiol Rev ,2002,15:125-144.
  • 2Andrews J M. Determination of minimum inhibitory concentrations. J Antimicrob Chemother, 2001,48 Suppl S1:5-16.
  • 3Du Plessis M. Rapid discrimination between BRO beta-lactamases from clinical isolates of Moraxella catarrhalis using restrion endonuclease analysis. Diagn Microbiol Infect Dis,2001,39,65-67.
  • 4Johnson DM, Sader H S ,Fritsche TR, et al. Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents:five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis,2003,47,373-376.
  • 5Bootsma H,Aerts PC,Posthuma G,et al. Moraxella(Branhamella)catarrhalis BRO beta-lactamase:a lippoprotein of gram-positive origin?J Bacteriol,1999,181:5090-5093.
  • 6Mcgregor K, Chang BJ, Mee B J. Moraxella Catarrhalis :Clinical significance ,antimicrobial susceptibility and BRO-lactamases. J Clin Microbiol Infect Dis,1998,17:219.

共引文献5

同被引文献10

引证文献1

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部